BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ma Y, Lee JW, Park SJ, Yi ES, Choi YB, Yoo KH, Sung KW, Koo HH. Detection of MYCN Amplification in Serum DNA Using Conventional Polymerase Chain Reaction. J Korean Med Sci 2016;31:1392-6. [PMID: 27510381 DOI: 10.3346/jkms.2016.31.9.1392] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Salazar LPB, Gaviria-delgado D, Guerrero MF, Osorio LK, Alvarez R, Cabrera E, Olaya N. Affordable panel of techniques for prediction of molecular classification of a series of medulloblastomas in a reference pediatric hospital in Colombia.. [DOI: 10.21203/rs.3.rs-2622116/v1] [Reference Citation Analysis]
2 Liang Y, Wang Q, Zhang X, Zhang M, Du B, Cheng W, Wang H, Li L, Hou G, Zhang W. Dual isothermal amplification all-in-one approach for rapid and highly sensitive quantification of plasma circulating MYCN gene of neuroblastoma. Anal Biochem 2022;:114922. [PMID: 36162447 DOI: 10.1016/j.ab.2022.114922] [Reference Citation Analysis]
3 Zhuo Z, Lin L, Miao L, Li M, He J. Advances in liquid biopsy in neuroblastoma. Fundamental Research 2022. [DOI: 10.1016/j.fmre.2022.08.005] [Reference Citation Analysis]
4 Liang Y, Liu Y, Zhang P, Zhang M, Du B, Cheng W, Yu Z, Li L, Wang H, Hou G, Zhang X, Zhang W. Plasma circulating cell-free MYCN gene: A noninvasive and prominent recurrence monitoring indicator of neuroblastoma. Cancer Rep (Hoboken) 2023;6:e1688. [PMID: 35892165 DOI: 10.1002/cnr2.1688] [Reference Citation Analysis]
5 Yang Y, Zhao J, Zhang Y, Feng T, Yv B, Wang J, Gao Y, Yin M, Tang J, Li Y. MYCN protein stability is a better prognostic indicator in neuroblastoma. BMC Pediatr 2022;22:404. [PMID: 35820898 DOI: 10.1186/s12887-022-03449-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Osei E, Al-ani N, Al-asady A, Dang S. Liquid biomarkers for the management of paediatric neuroblastoma: an approach to personalised and targeted cancer therapy. J Radiother Pract 2021;20:217-229. [DOI: 10.1017/s1460396920000102] [Reference Citation Analysis]
7 Wei M, Ye M, Dong K, Dong R. Circulating tumor DNA in neuroblastoma. Pediatr Blood Cancer 2020;67:e28311. [PMID: 32729220 DOI: 10.1002/pbc.28311] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Trigg RM, Shaw JA, Turner SD. Opportunities and challenges of circulating biomarkers in neuroblastoma. Open Biol 2019;9:190056. [PMID: 31088252 DOI: 10.1098/rsob.190056] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]